It has been suggested that fluid accumulation may delay recognition of acute kidney injury. We sought to determine the impact of fluid balance on the incidence of nondialysis requiring acute kidney injury in patients with acute lung injury and to describe associated outcomes, including mortality.
Analysis of the Fluid and Catheter Treatment Trial, a factorial randomized clinical trial of conservative vs. liberal fluid management and of management guided by a central venous vs. pulmonary artery catheter.
Acute Respiratory Distress Syndrome Network hospitals.
One thousand patients.
The incidence of acute kidney injury, defined as an absolute rise in creatinine of ≥0.3 mg/dL or a relative change of >50% over 48 hrs, was examined before and after adjustment of serum creatinine for fluid balance. The incidence of acute kidney injury before adjustment for fluid balance was greater in those managed with the conservative fluid protocol (57% vs. 51%, p = .04). After adjustment for fluid balance, the incidence of acute kidney injury was greater in those managed with the liberal fluid protocol (66% vs. 58%, p = .007). Patients who met acute kidney injury criteria after adjustment of creatinine for fluid balance (but not before) had a mortality rate that was significantly greater than those who did not meet acute kidney injury criteria both before and after adjustment for fluid balance (31% vs. 12%, p < .001) and those who had acute kidney injury before but not after adjustment for fluid balance (31% vs. 11%, p = .005). The mortality of those patients meeting acute kidney injury criteria after but not before adjustment for fluid balance was similar to patients with acute kidney injury both before and after adjustment for fluid balance (31% vs. 38%, p = .18).
Fluid management influences serum creatinine and therefore the diagnosis of acute kidney injury using creatinine-based definitions. Patients with “unrecognized” acute kidney injury that is identified after adjusting for positive fluid balance have higher mortality rates, and patients who have acute kidney injury before but not after adjusting for fluid balance have lower mortality rates. Future studies of acute kidney injury should consider potential differences in serum creatinine caused by changes in fluid balance and the impact of these differences on diagnosis and prognosis.
From the Divisions of Nephrology and Critical Care Medicine (KDL) and the Division of Pulmonary and Critical Care Medicine (MAM), University of California San Francisco, San Francisco, CA; the Pulmonary and Critical Care Unit (BTT), Departments of Medicine and Biostatistics (MA), Massachusetts General Hospital, Boston, MA; the Division of Critical Care Medicine (JSS), Baystate Medical Center, Springfield, MA, and Tufts University School of Medicine, Boston, MA; the Division of Pulmonary Sciences and Critical Care Medicine (ISD), University of Colorado and Denver Health Medical Center, Denver, CO; Pulmonary and Critical Care Medicine (PW), Moses Cone Hospital, Greensboro, NC; the Department of Medicine (MWP), University of California San Francisco at Fresno, Fresno, CA; the Department of Anesthesiology (PR), University of Maryland, Baltimore, MD; Pulmonary and Critical Care Medicine (RCH), University of Michigan, Ann Arbor, MI; Pulmonary and Critical Care Medicine (AA), South Texas Veterans Health Care System and University of Texas Health Sciences Center at San Antonio, San Antonio, TX; and the Division of Pulmonary and Critical Care Medicine (JDT), University of Virginia, Charlottesville, VA.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (http://www.ccmjournal.com).
All authors were supported by contracts NO1-HR-46046-64 and NO1-HR-16146-54 with the National Heart, Lung, and Blood Institute, National Institutes of Health. K.D.L. was supported by National Institutes of Health/National Center for Research Resources/OD University of California–San Francisco–CTSI Grant Number KL2 RR024130.
Dr. Wright received honoraria/speaking fees from GlaxoSmithKline. The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: firstname.lastname@example.org